These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36093549)

  • 1. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
    Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
    Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
    Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
    J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
    Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
    Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
    Hua Y; Huang X; Li C; Gao N
    Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.
    Ma R; Wang JL; Wang YY
    Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.
    Wang C; Lei K; Jia Y; Jiang Z; Wang S
    Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report.
    Liu J; Cao G; Zhang G; Liu S; Shi D
    J Gastrointest Oncol; 2023 Jun; 14(3):1643-1649. PubMed ID: 37435210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
    Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
    Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
    Chen Y; Zhang H; Shi J; Wang T
    Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
    Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
    Song G; Zhang FF; Cheng HD
    Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
    He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
    J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
    Qu W; Wang F; Qin S; Sun Y; Huang C
    Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia.
    Fu S; Li C; Wang Z; Zhong Z; Zhong Y
    Medicine (Baltimore); 2023 Jun; 102(26):e34120. PubMed ID: 37390264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 67-Year-Old Man with Grade 3 Reactive Cutaneous Capillary Endothelial Proliferation Induced by Camrelizumab First Manifested in the Oral Mucosa - A Case Report.
    Liu Y; Liu H; Bian Q; Guan Y
    Int J Surg Pathol; 2024 Jun; 32(4):803-809. PubMed ID: 37723943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation.
    Liu Y; Chen T; Zhang C; Pan W
    Indian J Dermatol; 2023; 68(1):85-90. PubMed ID: 37151267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report.
    Wang J; Li S; Zhang L; Zhang X
    J Cancer Res Ther; 2023 Feb; 19(1):141-143. PubMed ID: 37006054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
    Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
    Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
    [No Abstract]   [Full Text] [Related]  

  • 19. Camrelizumab: an investigational agent for hepatocellular carcinoma.
    Xu B; Sun HC
    Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
    Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
    Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.